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BACKGROUND: Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM-1] or CD248), 
which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxi-
zumab in patients with sarcoma. METHODS: Part 1 was an open-label, dose-finding, safety lead-in: 4, 6, or 8 mg/kg with gemcitabine 
and docetaxel (G/D; 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8). In part 2, patients were randomized 
in a double-blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological 
cohorts. RESULTS: In part 2 with 209 patients, no significant difference in progression-free survival between ontuxizumab plus G/D 
(4.3 months; 95% confidence interval [CI], 2.7-6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6-8.3 months) was 
observed (P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77-1.49). Similarly, there was no significant difference in median overall survival 
between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2-21.1 months) and 21.1 months for the placebo 
plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82-1.82). No significant differences between the 
treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally 
well tolerated. CONCLUSIONS: Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft-tissue sarco-
mas, whereas the safety profile of the combination was consistent with G/D alone. Cancer 2019;125:2445-2454. © 2019 The Authors. 
Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of 
the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided 
the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
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INTRODUCTION
Soft-tissue sarcomas are rare solid tumors of mesenchymal origin with more than 50 different histological subtypes, each 
with its own underlying biology.1 Despite optimal surgery, approximately 50% of patients will develop metastatic disease. 
The outcome of patients with metastatic disease is poor, with a median overall survival (OS) of 12 to 20 months and with few 
systemic therapy options.1 Consequently, there is an unmet need for more effective systemic therapies for advanced sarcomas.
Endosialin, or tumor endothelial marker 1 (TEM-1), is a cell surface glycoprotein that is expressed in the stromal 
compartment of nearly all human tumors.2 Preclinical studies have shown that endosialin plays a key role in tumor 
growth and vessel formation in numerous tumor types, including sarcomas.3,4 Endosialin expression was noted in all 
9 sarcoma subtypes and in 83% of all sarcoma specimens.2 Rouleau et al2 demonstrated that endosialin was expressed by 
malignant, perivascular, and stromal cells in human specimens. Endosialin expression was found in human specimens 
of high-grade/advanced sarcomas.5 Consequently, endosialin was considered a potential therapeutic target in sarcomas. 
Other studies confirmed these findings.6
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Ontuxizumab is a humanized immunoglobulin G1κ 
antibody directed against endosialin and the first of this 
class to undergo clinical evaluation. Nonclinical phar-
macological studies have shown that ontuxizumab has 
the ability to interfere with specific endosialin receptor- 
ligand interactions.7 The combination of gemcitabine 
and docetaxel (G/D) is well established in the treatment 
of metastatic sarcomas.8 The aim of this trial was to 
 assess the optimal dose of ontuxizumab in combination 
with G/D and to evaluate the ability of the antibody to 
enhance the antitumor activity of G/D.
MATERIALS AND METHODS
Patients
Patients older than 18 years with histologically proven 
metastatic soft-tissue sarcomas and an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 
0 to 1 were eligible. In addition, patients had to have meas-
urable disease according to version 1.1 of the Response 
Evaluation Criteria in Solid Tumors (RECIST), to have 
been treated with 0 to 2 prior lines of systemic therapy, 
and to have fully recovered from all toxicities of previ-
ous treatments (apart from alopecia). Patients had to have 
 adequate hematologic, renal, and liver parameters and no 
brain metastases, primary bone sarcomas, other active 
malignancies, or an uncontrolled medical condition.
Before enrollment was commenced, local institu-
tional review board/ethics committee approval was ob-
tained in accordance with the Declaration of Helsinki. 
Investigators obtained informed consent from each 
participant.
Study Design and Treatment
This was a multicenter, sequential, 2-part trial. Part 1 
was an open-label, dose-escalation design used to es-
tablish the safety of ontuxizumab combined with G/D 
and to define the recommended phase 2 dose. The dose- 
escalation phase consisted of ontuxizumab (days 1 and 
8 of a 21-day cycle) in combination with gemcitabine at 
900 mg/m2 (days 1 and 8) and docetaxel at 75 mg/m2 
(day 8).
The recommended phase 2 dose was defined as the 
highest ontuxizumab dose administered in combination 
with G/D at which 0 of 3 patients or no more than 1 
of a maximum of 6 patients in a given dose cohort ex-
perienced a dose-limiting toxicity (DLT). Patients were 
treated until disease progression. A DLT was defined as 
treatment-related and occurring within the first 28 days 
of treatment. DLTs included 1) a nonhematologic 
toxicity of grade 3 or higher (excluding grade 3 asthe-
nia unless lasting longer than 3 days, nausea/vomiting 
unless optimally treated, and alopecia); 2) a hema-
tologic toxicity of grade 4 neutropenia lasting lon-
ger than 7 days, grade 4 febrile neutropenia, a grade 
3/4 infection with associated grade 3/4 neutropenia, 
a grade 4 hematologic toxicity not resolving in fewer 
than 14 days, or grade 3 thrombocytopenia with clin-
ically significant bleeding; 3) delayed recovery caus-
ing a delay of the next dose longer than 28 days; and 
4) an infusion-related toxicity excluding those con-
trolled to grade 2 or lower by management and ana-
phylactic reactions.
Part 2 was a randomized, double-blind, placebo- 
controlled trial of G/D with either 8 mg/kg ontuxizumab 
or a placebo and used the same doses and schedule used 
in part 1. Patients were randomly assigned in a 2:1 ratio 
to ontuxizumab plus G/D or the placebo plus G/D and 
were stratified into 4 sarcoma cohorts.
Study Assessments
The response to treatment was determined by computed 
tomography or magnetic resonance imaging performed 
at screening and every 6 weeks for the first 24 ± 1 weeks 
and then every 12 weeks. Patients who discontinued the 
study drug were followed for documentation of disease 
progression, any additional anticancer therapies, and 
survival.
The primary endpoint for part 2 was progression- 
free survival (PFS). Secondary endpoints included OS, 
the overall response rate based on RECIST 1.1, safety, 
and tolerability. Exploratory objectives included the eval-
uation of putative predictive markers of response.
Safety was evaluated by the monitoring of adverse 
events (AEs; graded via Common Toxicity Criteria for 
Adverse Events, version 4.03), serious adverse events (SAEs), 
laboratory measurements, vital signs, electrocardiograms, 
ECOG assessments, and physical examinations.
Biomarkers, Antidrug Antibody,  
and Pharmacokinetic Analysis
Tumor tissue was obtained from all patients from an ini-
tial diagnostic tissue sample or an optional biopsy dur-
ing screening or previous treatment. Formalin-fixed, 
paraffin-embedded slides underwent immunohisto-
chemistry for endosialin and platelet-derived growth 
factor receptor β (PDGFR-β), as previously described,7,9 
with endosialin antibody clone 9G5 (Morphotek, 
Exton, Pennsylvania) and PDGFR-β antibody 28E1 
(Cell Signaling Technology, Danvers, Massachusetts). 
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Immunohistochemistry was validated and performed 
by PhenoPath Laboratories (Seattle, Washington). The 
tumor content of slides was reviewed, and tissues controls 
were incorporated into each run.
Slides were evaluated by a board-certified patholo-
gist as percentages of cells with expression at intensities of 
0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). 
The level of biomarker expression in each subcompart-
ment was assessed as the M score, which was calculated 
as [(% of population scoring 1+) + (2 × % of population 
scoring 2+) + (3 × % of population scoring 3+)]/6.
Baseline serum biomarkers were assayed to quanti-
tate the levels of endosialin and PDGFR-β as previously 
described.10 The detection of the ontuxizumab antidrug 
antibody in serum samples was performed as previously 
described.11 Serum concentrations of ontuxizumab 
were measured at each cycle for pharmacokinetic anal-
ysis. Ontuxizumab concentrations were measured with 
an  endosialin antigen–based electrochemiluminescent 
 immunoassay to capture and quantify the serum concen-
tration of free/partially complexed ontuxizumab.11
Statistics
Parts 1 and 2 of the study were summarized and analyzed 
separately. The sample size was planned to be a maxi-
mum of 19 patients for part 1 and 225 patients for part 
2 (120-200 patients in part 2, with a particular sarcoma 
cohort to have no more than 60 patients). An independ-
ent, unblinded committee monitored the trial. Part 1 
data were summarized descriptively by dose level.
In part 2, the primary analysis of PFS was con-
ducted at the time at which 185 PFS events (progres-
sion or death) were observed; Kaplan-Meier curves were 
used, with 95% confidence intervals (CIs) for medians 
calculated according to Brookmeyer and Crowley.12 PFS 
in treatment groups was compared in the intent-to-treat 
population on the basis of the log-rank test, and the haz-
ard ratio (HR) was estimated on the basis of the Cox 
proportional hazards model. These analyses were also 
conducted separately by sarcoma cohort. OS was sum-
marized in a similar manner.
The overall response rate (complete or partial) was 
summarized with 95% CIs with the Clopper-Pearson 
exact binomial CI13 for each treatment group. To identify 
differences between treatment groups overall and within 
sarcoma cohorts, a Bayesian hierarchical model was used 
to model PFS across the 4 strata.14 Safety data were sum-
marized with descriptive statistics.
Cox regression modeling was used to assess the 
influence of baseline tissue and serum biomarkers as 
covariates on PFS and OS. If the univariate regression 
model P value (with the Wald chi-square test) for the fac-
tor was <.2, then the factor was included as a candidate 
for inclusion in a stepwise selection process using a multi-
variate Cox regression model. Interactions between treat-
ment and each factor were explored to assess each factor’s 
ability to predict a clinical response. Exposure-response 
relations were evaluated with Kaplan-Meier curves and 
were characterized in terms of median PFS and OS with 
2-sided 95% CIs constructed with the methodology of 
Brookmeyer and Crowley.12
RESULTS
Part 1
Sixteen patients enrolled in part 1. Two dose levels of 
 ontuxizumab (4 and 8 mg/kg) were planned in combina-
tion with G/D. No DLTs were observed in the 3  patients 
treated within cohort 1 (ontuxizumab at 4 mg/kg). 
One of the 6 patients in cohort 2 (ontuxizumab at 
8 mg/kg) experienced grade 4 febrile neutropenia. An 
additional patient in cohort 2 experienced a non-DLT 
event of grade 4 neutropenia. Both patients in cohort 
2 had previously received more than 6 months of com-
bination chemotherapy. Therefore, the G/D reduction 
criterion was amended to require a decrease of 25% of 
the starting dose for G/D for those previously treated 
with more than 6 months of combination chemother-
apy. With this new criterion, 2 further de-escalation 
dose cohorts (cohorts 3 and 4) were opened. In cohort 3, 
the dose was decreased to 6 mg/kg, and no DLTs were 
observed. Therefore, the dose was re-escalated to 8 mg/kg 
in cohort 4, and no additional DLTs were observed.
In total, 3 patients received 4 mg/kg ontuxizumab, 
4 patients received 6 mg/kg ontuxizumab, and 9 patients 
received 8 mg/kg ontuxizumab. The recommended 
phase 2 dose of ontuxizumab in combination with G/D 
was 8 mg/kg. There were no treatment-related deaths or 
SAEs, and there were no AEs resulting in discontinua-
tion from the trial in part 1.
Part 2
A total of 255 patients were screened for entry into part 2, 
and 209 were randomized. Among the 46 screen failures, 
2 patients (0.8%) did not have measurable disease by 
RECIST 1.1, 1 patient (0.4%) failed to meet inclusion/
exclusion criteria, and 43 patients (16.9%) were excluded 
for other reasons.
Patients were enrolled at 31 sites in the United 
States, Australia, and Europe and randomized to either 
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ontuxizumab plus G/D (139 patients) or the placebo 
plus G/D (70 patients) and were included in the intent- 
to-treat population.
Of the 209 randomized patients, 2 in the ontuxi-
zumab plus G/D arm discontinued the trial before dos-
ing, 1 because of death from progressive disease and 1 
because of complications of hypertension. A total of 207 
patients received at least 1 dose of ontuxizumab plus 
G/D or the placebo plus G/D, and 204 of these patients 
(98.6%) discontinued the trial.
The baseline disease characteristics are displayed 
in Table 1. The study population consisted of 114 
males (55%), and the median age was 56 years (range, 
21-81 years). The proportion of patients with a baseline 
ECOG score of 1 was higher in the ontuxizumab plus 
G/D group (72 of 139 patients or 52%) than the placebo 
plus G/D group (31 of 70 patients or 44%).
The duration of treatment for the ontuxizumab 
plus G/D group was a mean of 5.1 months (range, 0.3-
21.4 months) with a mean relative dose intensity of 97%. 
The duration of treatment for the placebo plus G/D 
group was 5.4 months (range, 0.3-21.2 months) with a 
mean relative dose intensity of 99.9%. Treatment delays 
associated with an AE occurred in 42% of the patients 
receiving ontuxizumab plus G/D and in 45% of the 
 patients receiving the placebo plus G/D. Dose reductions 
occurred in 8% of the patients in both arms.
There was no significant difference between treat-
ment arms for PFS. The median PFS was 4.3 months 
(95% CI, 2.7-6.3 months) in the ontuxizumab plus G/D 
arm and 5.6 months (95% CI, 2.6-8.3 months) in the 
placebo plus G/D arm (P = .67; HR, 1.07; 95% CI, 0.77-
1.49). The Kaplan-Meier curves for PFS are displayed in 
Figure 1. No significant difference between treatment 
arms was apparent by sarcoma cohort (Table 2).
There was no significant difference in median 
OS between the 2 arms: 18.3 months (95% CI, 16.2-
21.1 months) in the ontuxizumab plus G/D arm and 
21.1 months (95% CI, 14.2 months to not reached) in 
the placebo plus G/D arm (P = .32; HR, 1.23; 95% 
TABLE 1. Baseline Characteristics for Patients Enrolled in Part 2 (Intent-To-Treat Population)
Ontuxizumab at 8 mg/kg + G/D (n = 139) Placebo + G/D (n = 70) Total (n = 209)
Age, mean (SD), y 55 (13) 54 (14) 55 (14)
Sex, No. (%)
Male 76 (55) 38 (54) 114 (55)
Female 63 (45) 32 (46) 95 (46)
Race, No. (%)
White 116 (83) 57 (81) 173 (83)
Black or African American 12 (9) 9 (13) 21 (10)
Other 11 (8) 4 (6) 15 (7)
Initial histologic diagnosis grade, No. (%)
1 3 (2) 4 (6) 7 (3)
2 21 (15) 13 (19) 34 (16)
3 82 (59) 38 (54) 120 (57)
Unknown 22 (16) 9 (13) 31 (15)
Missing 11 (8) 6 (9) 17 (8)
Baseline ECOG performance status, No. (%)
0 67 (48) 39 (56) 106 (51)
1 72 (52) 31 (44) 103 (49)
Prior chemotherapy in the metastatic setting 74 (53) 40 (57) 114 (55)
First line 65 (47) 30 (43) 95 (45)
Second line 53 (38) 29 (41) 82 (39)
Third line 21 (15) 11 (16) 32 (15)
Histologic subtype, No. (%)
Liposarcoma 30 (22) 15 (21) 45 (22)
Leiomyosarcoma 41 (29) 21 (30) 62 (30)
Undifferentiated pleomorphic sarcoma  
or myxofibrosarcoma
30 (22) 15 (21) 45 (22)
Other 38 (27) 19 (27) 57 (27)
Angiosarcoma 3 2 5
Spindle cell sarcoma 3 2 5
Peripheral nerve sheath tumor 6 1 7
Synovial sarcoma 14 6 20
Miscellaneous or unclassifieda 12 8 20
Abbreviations: ECOG, Eastern Cooperative Oncology Group; G/D, gemcitabine and docetaxel; SD, standard deviation.
aThe miscellaneous and unclassified histologic subtypes included patients with histologic diagnoses of rhabdomyosarcoma (3), unclassified sarcoma (3), epi-
thelioid sarcoma (3), hemangiopericytoma (2), endometrial sarcoma (2), adenosarcoma (1), clear cell sarcoma (1), fibrosarcoma (1), intimal sarcoma (1), phyl-
lodes (1), other liposarcoma (1), and small blue round cell tumor (1).
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CI, 0.82-1.83). The Kaplan-Meier curves for OS are 
 displayed in Figure 2.
The only sarcoma cohort with a longer median 
PFS in the ontuxizumab group was the “other” cohort. 
The other cohort comprised at least 13 different histo-
logical subtypes and included angiosarcomas (n = 5), 
spindle cell sarcomas (n = 5), peripheral nerve sheath 
tumors (n = 7), synovial sarcomas (n = 20), and miscel-
laneous types (n = 20). Patients with spindle cell sarcoma 
treated with ontuxizumab had longer median PFS and 
OS than patients treated with the placebo (median PFS, 
2.8 months with ontuxizumab and 1.6 months with the 
placebo; median OS, 10.7 months with ontuxizumab 
and 2.0 months with the placebo). Patients treated with 
ontuxizumab in the miscellaneous subcategory also had 
longer median PFS and OS than patients treated with the 
placebo. These were exploratory analyses, and no statisti-
cal comparisons were made.
There was no significant difference in the over-
all response rate between the 2 arms (P = 1.00) or by 
sarcoma cohort (P < .2 for HR <0.75). Three patients 
achieved a complete response: 1 (1%) was treated with 
ontuxizumab plus G/D, and 2 (3%) were treated with 
the placebo plus G/D. A partial response was achieved 
by 38 patients: 26 (19%) were treated with ontuxizumab 
plus G/D, and 12 (17%) were treated with the placebo 
plus G/D. Sixty patients (43%) in the ontuxizumab plus 
G/D arm and 33 patients (47%) in the placebo plus 
G/D arm had stable disease as their best response.
At trial termination, 2 patients with partial  responses 
continued ontuxizumab. Both patients achieved a partial 
response at cycle 17 that continued for more than 2 years 
on therapy.
Safety
All patients in the ontuxizumab plus G/D arm and 
the placebo plus G/D arm had at least 1 treatment- 
emergent AE; the most common (in ≥40% of all 
 patients) were fatigue (74% vs 66%), anemia (61% vs 
60%), nausea (56% vs 52%), diarrhea (44% vs 36%), 
peripheral edema (42% vs 45%), and thrombocytope-
nia (41% vs 43%) respectively.
A numerically higher proportion of patients in the 
ontuxizumab plus G/D group (86%) versus the placebo 
plus G/D group (76%) had treatment-emergent AEs 
that were considered related to the treatment (Table 3). 
Figure 1. Kaplan-Meier curves of progression-free survival for all sarcoma subtypes in part 2 (intent-to-treat population). 
CI indicates confidence interval; G/D, gemcitabine and docetaxel.
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Treatment-related AEs that occurred in a higher propor-
tion of patients (>10% difference) in the ontuxizumab 
plus G/D arm than the placebo plus G/D arm included 
fatigue, headache, pyrexia, diarrhea, and vomiting. Rash 
occurred more frequently in the placebo plus G/D arm 
(18 of 67 or 27%) than the ontuxizumab plus G/D arm 
(16 of 140 or 11%).
The frequencies of patients with at least 1 SAE were 
similar in the 2 arms: 50% in the ontuxizumab plus G/D 
arm and 48% in the placebo plus G/D arm. The most 
frequent treatment-related SAEs were pyrexia (3% over-
all, 4% in the ontuxizumab plus G/D arm, and 0% in 
the placebo plus G/D arm) and anemia (2% overall, 1% 
in the ontuxizumab plus G/D arm, and 3% in the pla-
cebo plus G/D arm). There were no differences in labora-
tory values, vital signs, or electrocardiogram parameters 
between the 2 arms.
One patient in each arm died of a treatment- 
related AE (cardiac arrest in the ontuxizumab plus 
G/D arm and respiratory failure in the placebo plus 
G/D arm arm). Two patients (1%) in the ontuxizumab 
plus G/D arm experienced drug hypersensitivity AEs 
(infusion-related reaction and pyrexia/f lushing); all 
were nonserious and grade 1. None of the drug hyper-
sensitivity AEs resulted in an interruption or discontin-
uation of ontuxizumab. One patient on ontuxizumab 
plus G/D developed a transient treatment-induced 
 antidrug antibody response.
Biomarkers and Pharmacokinetics
Baseline tumor tissue expression of endosialin and 
PDGFR-β were measured in the subcompartments of 
arterial endothelial, capillary endothelial, cytoplasmic 
tumor endothelial, lymphatic endothelial, membranous 
tumor endothelial, nonvascular stromal, perivascular, 
and venous endothelial cells (Table 4). No significant 
difference in baseline biomarker expression between 
arms was observed. The highest levels of endosialin 
were measured in nonvascular stromal, perivascu-
lar, and venous endothelial cells. The highest levels 
of PDGFR-β were measured in capillary endothelial, 
 cytoplasmic tumor, lymphatic endothelial, nonvascular 
stromal, and perivascular cells.
A prognostic biomarker demonstrates an association 
with outcome, regardless of therapy. Factors considered 
possibly prognostic of PFS included the log serum endo-
sialin concentration (P = .06), tissue endosialin in venous 
endothelial cells (P = .04), and tissue PDGFR-β in capil-
lary endothelial cells (P = .10). Longer PFS was associated 
with higher serum endosialin concentrations (HR, 0.61; 
95% CI, 0.36-1.03), lower tissue endosialin expression in 
venous endothelial cells (HR, 1.01; 95% CI, 1.0-1.02), 
and lower tissue PDGFR-β levels in capillary endothelial 
cells (HR, 0.74; 95% CI, 0.51-1.06). Factors considered 
possibly prognostic of OS were endosialin cytoplasmic 
tumor endothelial cells (P = .09) and endosialin mem-
branous tumor endothelial cells (P = .12). Longer OS 
was associated with lower tissue endosialin levels in 
cytoplasmic tumor endothelial cells (HR, 1.01; 95% 
CI, 1.0-1.02) and higher tissue endosialin expression in 
membranous tumor endothelial cells (HR, 1.02; 95% 
CI, 1.0-1.04).
A predictive biomarker provides information 
about the effect of a therapeutic intervention on clin-
ical outcomes and can potentially be used to select 
patients for therapy. Tissue PDGFR-β in capillary 
 endothelial cells showed a significant treatment interac-
tion (P = .02), with values below the median associated 
with improved PFS (HR, 0.55, 95% CI, 0.29-1.04). No 
TABLE 2. PFS With the Bayesian Hierarchical 
Model in Part 2
Sarcoma Type
Ontuxizumab at 
8.0 mg/kg + G/D Placebo + G/D
Liposarcoma
No. 30 15
PFS observed, median, wk 14.6 24.1
Hazard ratio (95% CI) 1.12 (0.69-1.89)
OS observed, median, wk 58.5 54.4
Hazard ratio (95% CI) 1.1 (0.56-1.87)
BOR (% with response) 20/30 (67) 12/15 (80)
P .236
Leiomyosarcoma
No. 41 21
PFS observed, median, wk 18.3 24.0
Hazard ratio (95% CI) 1.08 (0.68-1.61)
OS observed, median, wk 64.6 69.1
Hazard ratio (95% CI) 1.3 (0.74-2.28)
BOR (% with response) 27/41 (66) 16/21 (76)
P .551
UPS
No. 30 15
PFS observed, median, wk 10.3 33.6
Hazard ratio (95% CI) 1.23 (0.73-2.09)
OS observed, median, wk 54.1 55.3
Hazard ratio (95% CI) 1.2 (0.68-2.00)
BOR (% with response) 16/30 (53) 11/15 (73)
P .174
Other
No. 38 19
PFS observed, median, wk 10.3 6.7
Hazard ratio (95% CI) 1.01 (0.60-1.54)
OS observed, median, wk 56.6 57.1
Hazard ratio (95% CI) 1.1 (0.63-1.70)
BOR (% with response) 24/38 (63) 8/19 (42)
P .389
Abbreviations: BOR, best overall response (stable disease, partial re-
sponse, or complete response); CI, confidence interval; G/D, gemcitabine 
and docetaxel; OS, overall survival; PFS, progression-free survival; UPS, 
undifferentiated pleomorphic sarcoma.
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baseline biomarkers were predictive of improved OS 
with ontuxizumab.
Ontuxizumab had no clear exposure effect on PFS 
or OS.
DISCUSSION
Ontuxizumab in combination with G/D was well tol-
erated in patients with soft-tissue sarcomas. Despite 
promising preclinical data and some durable benefit in 
patients with sarcoma treated within phase 1 trials,11 the 
combination did not show superior activity in compari-
son with G/D alone in this randomized trial. This was 
consistent in all 4 histological cohorts studied in the ran-
domized component of the trial.
The G/D combination was used in this study 
 because it has proven efficacy in advanced sarcomas.8,15,16 
Figure 2. Kaplan-Meier curves of overall survival for all sarcoma subtypes in part 2 (intent-to-treat population). CI indicates 
confidence interval; G/D, gemcitabine and docetaxel.
TABLE 3. Treatment-Emergent Adverse Events Considered Related to the Treatment by the Investigator in 
≥15% of Patients in Either Treatment Group in Part 2 (Safety Population)
Preferred Terma Ontuxizumab at 8 mg/kg + G/D (n = 140), No. (%) Placebo + G/D (n = 67), No. (%) Total (n = 207), No. (%)
Fatigue 66 (47) 23 (34) 89 (43)
Nausea 44 (31) 15 (22) 59 (29)
Headache 42 (30) 9 (13) 51 (25)
Anemia 39 (28) 18 (27) 57 (28)
Pyrexia 35 (25) 8 (12) 43 (21)
Diarrhea 31 (22) 6 (9) 37 (18)
Thrombocytopenia 29 (21) 11 (16) 40 (19)
Edema, peripheral 28 (20) 13 (19) 41 (20)
Decreased appetite 28 (20) 10 (15) 38 (18)
Myalgia 25 (18) 5 (8) 30 (15)
Vomiting 24 (17) 3 (4) 27 (13)
Chills 21 (15) 3 (5) 24 (12)
Rash 16 (11) 18 (27) 34 (16)
Abbreviation: G/D, gemcitabine and docetaxel.
aAdverse events were coded with the Medical Dictionary for Drug Regulatory Activities, version 14.1.
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A previous trial reporting a median PFS of 7.5 months with 
G/D and bevacizumab17 provided support for the combi-
nation of G/D with antiangiogenic agents in sarcomas.
Ontuxizumab was used in this trial to evalu-
ate the hypothesis that blocking endosialin-mediated 
tumor angiogenesis would enhance the efficacy of G/D 
in sarcomas. However, no improvement in PFS or OS 
was observed with ontuxizumab. A major difficulty in 
conducting trials for sarcomas is the profound hetero-
geneity of these diseases. One of the goals of this trial 
was to evaluate the benefit of ontuxizumab in all soft- 
tissue sarcomas as well as specific cohorts to potentially 
identify subsets that might benefit from ontuxizumab. 
Ontuxizumab showed no additional benefit in liposar-
coma, leiomyosarcoma, or undifferentiated pleomorphic 
sarcoma. However, in the heterogeneous “other” cohort, 
longer median PFS (not statistically significant) was 
 observed with ontuxizumab. To evaluate potential ben-
efits in specific subtypes included in the other cohort, 
we performed an exploratory analysis. The spindle cell 
and miscellaneous sarcoma subcategories showed a non-
significantly but numerically longer median PFS with 
ontuxizumab treatment.
The choice of the ontuxizumab dose in this trial 
was based on the completed phase 1 trial of single-agent 
ontuxizumab with a maximum tolerated dose of 
12 mg/kg.11 One potential criticism of our trial is that the 
dose of ontuxizumab was not high enough. In the phase 
1 study, pharmacokinetic data suggested an accumulation 
of ontuxizumab at 4 mg/kg, and exposures were similar 
between 8 and 12 mg/kg with weekly administration. For 
this reason, the decision was made a priori not to go above 
8 mg/kg ontuxizumab in combination with G/D for the 
current trial. Because of the potential accumulation of 
ontuxizumab at doses higher than 4 mg/kg, we may not 
have given a high enough dose of ontuxizumab. However, 
pharmacokinetic analyses indicated that ontuxizumab ex-
posure had no effect on PFS or OS.
The profile of AEs occurring more frequently in 
the ontuxizumab arm (fatigue, headache, pyrexia, di-
arrhea, and vomiting) resembles the profile of the most 
frequent AEs observed in the phase 1 trial.11 These re-
sults suggest that ontuxizumab did have a pharmaco-
logical effect in the current trial. Whether this dose 
was sufficiently high to block the angiogenic effect of 
endosialin is not certain.
Endosialin is believed to increase the proliferation 
of pericytes and result in enhanced tumor angiogenesis 
via a platelet-derived growth factor receptor signaling 
pathway.3 In the current trial, patients were not selected 
on the basis of endosialin expression.
A longer PFS was associated with a higher serum 
endosialin concentration, a lower tissue endosialin 
 expression in venous endothelial cells, and a lower 
tissue PDGFR-β level in capillary endothelial cells at 
the baseline. Among ontuxizumab-treated patients, a 
lower tissue PDGFR-β expression in capillary endothe-
lial cells was associated with improved PFS, and this 
indicated that it was a potential predictive indicator of 
improved PFS with ontuxizumab.
Although compelling evidence linked the expres-
sion of endosialin with tumor growth and progression 
in preclinical studies, the biomarkers measured in this 
trial showed no predictive association with outcome in 
the ontuxizumab plus G/D arm. One potential reason 
for the weak association between endosialin-associated 
biomarkers and outcome is the low efficacy of ontuxi-
zumab in this trial.
TABLE 4. Mean Baseline Biomarker Values for Patients Enrolled in Part 2 (Intent-To-Treat Population)
Biomarker Ontuxizumab at 8 mg/kg + G/D (n = 139) Placebo + G/D (n = 70)
Endosialin lymphatic endothelial cell M score 12.8 13.3
Endosialin membranous tumor cell M score 4.2 4.3
Endosialin nonvascular stromal cell M score 18.3 18.7
Endosialin perivascular cell M score 24.1 22.9
Endosialin venous endothelial cell M score 19.1 16.8
Log plasma endosialin, ng/mL 11.463 11.486
PDGFR-β arterial endothelial cell M score 3.4 3.2
PDGFR-β capillary endothelial cell M score 30.0 29.0
PDGFR-β cytoplasmic tumor cell M score 22.7 21.5
PDGFR-β lymphatic endothelial cell M score 22.0 21.7
PDGFR-β membranous tumor cell M score 8.3 4.7
PDGFR-β nonvascular stromal cell M score 21.4 23.4
PDGFR-β perivascular cell M score 31.8 29.8
PDGFR-β venous endothelial cell M score 3.6 3.5
Log plasma PDGFR-β, ng/mL 7.830 7.872
Abbreviations: G/D, gemcitabine and docetaxel; PDGFR-β, platelet-derived growth factor receptor β.
Ontuxizumab in Metastatic Soft-Tissue Sarcomas/Jones et al
2453Cancer  July 15, 2019
On the basis of these data, further trials of 
 ontuxizumab for soft-tissue sarcomas are not warranted. 
Because of the stratification by subtype, this trial pro-
vides a benchmark of the subtype-specific efficacy of 
G/D. In the future, the potential use of antibody-drug 
conjugates to selectively deliver cytotoxic agents to tumor 
sites could be evaluated. Because endosialin is highly 
 expressed in sarcomas,2,5 ontuxizumab could be used to 
target sarcoma cells and deliver cytotoxic agents linked 
to it. In a human endosialin-positive sarcoma xenograft 
model, prolonged antitumor activity of an anti-endosialin 
antibody conjugated to cytotoxic agents was  observed in 
comparison with controls.18
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